Business Standard

Analysts' corner

Dr Reddy's Labs & Indraprastha Gas

Related News

DR REDDY’S LABS
Reco price: Rs 1,709;
Target price: Rs 1,950
Dr Reddy’s (DRRD) has filed an abbreviated new drug application for singulair granules oral formulation, used for treatment of asthma in children. Innovator Merck has sued DRRD for infringement of a patent on this, which expires in October 2022. This product has $80 million annual sales in the US. DRRD can launch earliest in September 14, after expiry of a 30-month stay on generic launch. Mylan and Teva could be the first to file on this product. Overweight.

HSBC Global Research

INDRAPRASTHA GAS
Reco price: Rs 346;
Target price: Rs 426
The Petroleum and Natural Gas Regulatory Board (PNGRB) has issued an order on network rates and compression charge for (IGL);. Against IGL’s proposed Rs 7.8/scm of network rate and compression charge, the PNGRB has allowed a mere Rs 3.1/scm, a decline of Rs 4.7/scm. Even after allowing for a marketing margin over and above this (the quantum of which, however, is uncertain), the order comes as a significant negative surprise, leading to a potential downside of 45-65 per cent to Citigroup’s Ebitda. Under this scenario, IGL will struggle to make even normative returns on the capital it has invested in the business. Maintain buy.

Citigroup

Read more on:   
|

Analysts' corner

Dr Reddy's Labs & Indraprastha Gas

Dr Reddy’s (DRRD) has filed an abbreviated new drug application for singulair granules oral formulation, used for treatment of asthma in children. Innovator Merck has sued DRRD for infringement of a patent on this, which expires in October 2022. This product has $80 million annual sales in the US. DRRD can launch earliest in September 14, after expiry of a 30-month stay on generic launch. Mylan and Teva could be the first to file on this product. Overweight.

DR REDDY’S LABS
Reco price: Rs 1,709;
Target price: Rs 1,950
Dr Reddy’s (DRRD) has filed an abbreviated new drug application for singulair granules oral formulation, used for treatment of asthma in children. Innovator Merck has sued DRRD for infringement of a patent on this, which expires in October 2022. This product has $80 million annual sales in the US. DRRD can launch earliest in September 14, after expiry of a 30-month stay on generic launch. Mylan and Teva could be the first to file on this product. Overweight.

HSBC Global Research

INDRAPRASTHA GAS
Reco price: Rs 346;
Target price: Rs 426
The Petroleum and Natural Gas Regulatory Board (PNGRB) has issued an order on network rates and compression charge for (IGL);. Against IGL’s proposed Rs 7.8/scm of network rate and compression charge, the PNGRB has allowed a mere Rs 3.1/scm, a decline of Rs 4.7/scm. Even after allowing for a marketing margin over and above this (the quantum of which, however, is uncertain), the order comes as a significant negative surprise, leading to a potential downside of 45-65 per cent to Citigroup’s Ebitda. Under this scenario, IGL will struggle to make even normative returns on the capital it has invested in the business. Maintain buy.

Citigroup

image

Read More

Axis Bank: Concerns reflect in valuations

Axis Bank posted good set of numbers for the quarter ended 31st March 2012, beating the consensus estimates. Higher than expected growth in interest ...

Recommended for you

Quick Links

Market News

BSE currency options segment largest in the world

Number of contracts in currency options segment had grown by nearly 30% in March

Nifty ends down 101 points; TCS down 4%, Lupin slumps 7%

The 30-share Sensex ended down 224 points at 28,442 and the 50-share Nifty ended down 101 points at 8,606.

Sensex ends down 242 points; IT shares drag

The 30-share Sensex provisionally ended down 242 points at 28,425 and the 50-share Nifty ended down 104 points at 8,603.

Pharma shares extend fall; CNX Pharma index down 3%

Lupin, Aurobindo, Sun Pharma, Cadila Healthcare, Venus Remedies, SPARC & Shasun Pharma down were 3%-7%.

CRISIL falls from record high on weak March quarter results

The stock down 8% to Rs 2,165 on the NSE after reporting 18% yoy drop in profit at Rs 56 crore in March 2015 quarter.

 

Back to Top